A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group.
Publication
, Journal Article
Jett, JR; Kirschling, RJ; Jung, SH; Marks, RS
Published in: Semin Oncol
June 1995
In 1994, approximately 34,000 to 43,000 Americans will be diagnosed with small cell lung cancer, and 60% to 70% of these individuals will have extensive-stage disease. The median survival time of patients with extensive-stage small cell lung cancer is 8 to 10 months and 10% or less will survive 2 years. There have been no major advances in the treatment of this stage of disease in the past decade. Phase II trials with promising new single-agent chemotherapeutic drugs are justifiable. We report the design and toxicity of a phase II trial with single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in previously untreated patients with extensive-stage small cell lung cancer.
Duke Scholars
Published In
Semin Oncol
ISSN
0093-7754
Publication Date
June 1995
Volume
22
Issue
3 Suppl 6
Start / End Page
75 / 77
Location
United States
Related Subject Headings
- Remission Induction
- Paclitaxel
- Oncology & Carcinogenesis
- Male
- Lung Neoplasms
- Humans
- Granulocyte Colony-Stimulating Factor
- Female
- Carcinoma, Small Cell
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Jett, J. R., Kirschling, R. J., Jung, S. H., & Marks, R. S. (1995). A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. Semin Oncol, 22(3 Suppl 6), 75–77.
Jett, J. R., R. J. Kirschling, S. H. Jung, and R. S. Marks. “A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group.” Semin Oncol 22, no. 3 Suppl 6 (June 1995): 75–77.
Jett JR, Kirschling RJ, Jung SH, Marks RS. A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. Semin Oncol. 1995 Jun;22(3 Suppl 6):75–7.
Jett, J. R., et al. “A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group.” Semin Oncol, vol. 22, no. 3 Suppl 6, June 1995, pp. 75–77.
Jett JR, Kirschling RJ, Jung SH, Marks RS. A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. Semin Oncol. 1995 Jun;22(3 Suppl 6):75–77.
Published In
Semin Oncol
ISSN
0093-7754
Publication Date
June 1995
Volume
22
Issue
3 Suppl 6
Start / End Page
75 / 77
Location
United States
Related Subject Headings
- Remission Induction
- Paclitaxel
- Oncology & Carcinogenesis
- Male
- Lung Neoplasms
- Humans
- Granulocyte Colony-Stimulating Factor
- Female
- Carcinoma, Small Cell
- 3211 Oncology and carcinogenesis